S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
NASDAQ:VAXX

Vaxxinity (VAXX) Stock Price, News & Analysis

$0.49
-0.04 (-7.59%)
(As of 04/12/2024 ET)
Today's Range
$0.48
$0.55
50-Day Range
$0.53
$0.86
52-Week Range
$0.48
$3.10
Volume
459,341 shs
Average Volume
400,147 shs
Market Capitalization
$61.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Vaxxinity MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,336.8% Upside
$7.00 Price Target
Short Interest
Bearish
9.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Vaxxinity in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.42) to ($0.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.27 out of 5 stars

Medical Sector

1585th out of 2,784 stocks

Pharmaceutical Preparations Industry

748th out of 1,293 stocks

VAXX stock logo

About Vaxxinity Stock (NASDAQ:VAXX)

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

VAXX Stock Price History

VAXX Stock News Headlines

Vaxxinity (NASDAQ:VAXX) Trading 2.1% Higher
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Vaxxinity & UCF to Collaborate on Space Medicine Research
See More Headlines
Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2023
Today
4/12/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VAXX
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+1,243.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-56,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$0.11 per share

Miscellaneous

Free Float
51,878,000
Market Cap
$66.05 million
Optionable
Not Optionable
Beta
2.39
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Louis Garfield Reese IV (Age 42)
    Co-Founder & Executive Chairman of the Board
    Comp: $83.28k
  • Ms. Mei Mei Hu J.D. (Age 41)
    CEO & Director
    Comp: $551.73k
  • Dr. Peter Powchik M.D. (Age 67)
    Executive VP, Global Scientific Director and Director
  • Mr. Jason Pesile CPA (Age 51)
    M.B.A., Senior Vice President of Finance & Accounting
  • Ms. Sumita Ray J.D. (Age 50)
    Chief Legal & Administrative Officer
  • Mr. Jon Harrison
    Chief Government Officer
  • Mr. Mark Joinnides MSE
    Chief of Staff
  • Ms. Amy B. Fix M.B.A.
    M.S., R.A.C., Chief Regulatory Officer
  • Dr. Jean-Cosme Dodart Ph.D.
    Senior Vice President of Research
  • Mr. Dario Mirski M.D.
    Senior Vice President of Neuro / Chronic Diseases

VAXX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxxinity stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VAXX shares.
View VAXX analyst ratings
or view top-rated stocks.

What is Vaxxinity's stock price target for 2024?

1 Wall Street analysts have issued 1 year target prices for Vaxxinity's stock. Their VAXX share price targets range from $7.00 to $7.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,336.8% from the stock's current price.
View analysts price targets for VAXX
or view top-rated stocks among Wall Street analysts.

How have VAXX shares performed in 2024?

Vaxxinity's stock was trading at $0.85 at the beginning of 2024. Since then, VAXX stock has decreased by 42.7% and is now trading at $0.4872.
View the best growth stocks for 2024 here
.

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VAXX earnings forecast
.

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) issued its earnings results on Monday, March, 27th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16).

What ETF holds Vaxxinity's stock?

Amplify Treatments, Testing and Advancements ETF holds 35,725 shares of VAXX stock, representing 0.58% of its portfolio.

When did Vaxxinity IPO?

Vaxxinity (VAXX) raised $90 million in an IPO on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share.

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VAXX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners